Brief: Helix Biopharma initiates enrollment in second dosing of lung cancer drug candidate
21/01/2016 21:36
Jan 21 (Reuters) - Helix Biopharma Corp HBP.TO : * Initiates enrollment in the second dosing cohort of U.S. combination treatment study of its lung cancer drug candidate l-dos47 * Source text for Eikon ID:nCCN1wkVBf * Further company coverage HBP.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020